News & Updates

Show Multimedia Only

Sublingual cyclobenzaprine fares well in fibromyalgia

17 Jun 2026 by

Findings from the phase III RESILIENT study show that a sublingual formulation of cyclobenzaprine (CBP SL) may benefit individuals with fibromyalgia.

Sublingual cyclobenzaprine fares well in fibromyalgia

17 Jun 2026

RMDs impact sexual health

15 Jun 2026 by

Rheumatic and musculoskeletal diseases (RMD) may negatively impact sexual well-being, a study suggests.

RMDs impact sexual health

15 Jun 2026

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

Rheumatology patients must undergo screening for anxiety, depression, FM: study

10 Jun 2026

A significant proportion of rheumatology patients have been diagnosed with anxiety, depression, or fibromyalgia (FM), reveals a study, noting the importance of including screening for clinical decisions at all routine encounters.

Rheumatology patients must undergo screening for anxiety, depression, FM: study

10 Jun 2026

$TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients$

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

10 Jun 2026

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

10 Jun 2026

Physical activity intensity matters more for chronic disease prevention

05 Jun 2026 by

Prioritizing physical activity (PA) intensity over volume may yield greater benefits for preventing most noncommunicable diseases (NCDs), a prospective study suggests.

Physical activity intensity matters more for chronic disease prevention

05 Jun 2026

Lifestyle factors, comorbidities linked to difficult-to-treat rheumatoid arthritis

04 Jun 2026

Difficult-to-treat rheumatoid arthritis is associated with smoking, obesity, fibromyalgia, and depression, according to the results of a meta-analysis.

Lifestyle factors, comorbidities linked to difficult-to-treat rheumatoid arthritis

04 Jun 2026

Leflunomide–hydroxychloroquine’s efficacy in Sjögren’s disease confirmed in RepurpSS-II trial

02 Jun 2026 by

Treatment with leflunomide in combination with hydroxychloroquine has been proven to be beneficial, helping reduce disease activity in patients with systemically active Sjögren’s disease, in the phase 2b RepurpSS-II trial.

Leflunomide–hydroxychloroquine’s efficacy in Sjögren’s disease confirmed in RepurpSS-II trial

02 Jun 2026

Antibiotics not supported for treating chronic low back pain with disc herniation

01 Jun 2026

Antibiotics seem to do nothing in terms of reducing pain in patients with chronic low back pain and disc herniation, a study has shown.

Antibiotics not supported for treating chronic low back pain with disc herniation

01 Jun 2026

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026 by

Taking ixekizumab and tirzepatide together results in higher rates of skin clearance and weight loss compared with ixekizumab alone in patients with psoriasis and overweight or obesity, who represent a population that is difficult to treat, according to the phase IIIb TOGETHER-PsO trial.

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Sublingual cyclobenzaprine fares well in fibromyalgia

Sublingual cyclobenzaprine fares well in fibromyalgia

RMDs impact sexual health

RMDs impact sexual health

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Rheumatology patients must undergo screening for anxiety, depression, FM: study

Rheumatology patients must undergo screening for anxiety, depression, FM: study

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

Physical activity intensity matters more for chronic disease prevention

Physical activity intensity matters more for chronic disease prevention

Lifestyle factors, comorbidities linked to difficult-to-treat rheumatoid arthritis

Lifestyle factors, comorbidities linked to difficult-to-treat rheumatoid arthritis

Leflunomide–hydroxychloroquine’s efficacy in Sjögren’s disease confirmed in RepurpSS-II trial

Leflunomide–hydroxychloroquine’s efficacy in Sjögren’s disease confirmed in RepurpSS-II trial

Antibiotics not supported for treating chronic low back pain with disc herniation

Antibiotics not supported for treating chronic low back pain with disc herniation

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI